ClinicalTrials.gg
RecruitingNCT07286292Updated Nov 12, 2026

Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

A Phase 2 interventional study of Vorasidenib in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation, sponsored by Institut de Recherches Internationales Servier (I.R.I.S.). Recruiting at 8 sites in 3 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Institut de Recherches Internationales Servier (I.R.I.S.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 12, 2026First site in Canada3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 553 studies in Astrocytoma with a site in United States — 52 open to participants now, 81 under way, 7 of them phase 3. Astrocytoma · United States.

Planned enrollment
371st of 457
10 · median 30
Started
2026
with 13 others
Phase 2
152 of 553
14 open now
Primary completion
2033-05
later than 77 of 80 live
Registered
541st of 553
by date

Among the 553 studies in Astrocytoma with a site in United States, this one is the 371st largest by planned enrollment of the 457 interventional ones that give a count, is one of 14 that started in 2026, is one of 152 in phase 2, reaches primary completion later than 77 of the 80 other live ones, and was the 541st registered.

Astrocytoma

688 studies on the registry are indexed under Astrocytoma; 80 are open to participants now.

Browse Astrocytoma studies →

Open to participants now

52 of the 553 studies in Astrocytoma with a site in United States are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Astrocytoma studies recruiting now, 40 (59%) set no upper age limit and 14 (21%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Astrocytoma with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety, tolerability, efficacy profile, and effect on growth and development of vorasidenib in pediatric participants aged 12 to \< 18 years old with grade 2 glioma with an IDH1 or IDH2 mutation. The study includes a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up period and a long-term follow-up period. The long-term follow-up period will assess participants for growth, development, and long-term safety impacts for approximately 5 years after the start of treatment or until Tanner Stage V is reached (whichever is later). Participants may undergo blood tests, heart tests (electrocardiogram (ECG)), imaging (MRI, X-ray), vital sign checks, and physical exams.

03

Conditions studied

  • Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weigh ≥ 25 kg at Screening.
  • Written /assent must be obtained from a legally authorized representative, and assent must be obtained from the participant in accordance with local regulations. Participants and their families must be willing and able to comply with the scheduled visits, treatment plans, procedures, and laboratory tests, including serial peripheral blood sampling, during the study.
  • Have Grade 2 astrocytoma or oligodendroglioma per World Health Organisation (WHO) 2021 criteria.
  • Have had at least 1 prior surgery for glioma (, sub-total resection, gross-total resection) and no other prior anticancer therapy, including chemotherapy and radiotherapy, and do not need immediate chemotherapy or radiotherapy in the opinion of the Investigator.
  • Have:
  • Confirmed IDH1 or IDH2 gene mutation, as well as known 1p19q and/or ATRX (Alpha Thalassemia/Mental Retardation Syndrome X-linked) status based on local testing of tumor tissue by an accredited laboratory.
  • For astrocytoma: Absence of 1p19q co-deletion and/or documented loss of nuclear ATRX expression or ATRX mutation by local testing.
  • For oligodendroglioma: Presence of 1p19q co-deletion by local testing.
  • Have magnetic resonance imaging (MRI)-evaluable, measurable, non-enhancing disease
  • Have a Performance Score (KPS; for participants ≥ 16 years of age) or Lansky Play-Performance Scale (LPPS; for participants \< 16 years of age) score of ≥ 70. Karnofsky Performance Score and LPPS \< 70 due to functional limitations as a result of prior surgical resections or due to the anatomical location of the tumor will be permitted.
  • Have adequate bone marrow function as evidenced by:
  • ≥ 1500/mm3 or ≥ 1.5 × 109/L
  • ≥ 9 g/dL
  • ≥ 100,000/mm3 or ≥ 100 × 109/L
  • Have adequate hepatic function as evidenced by:
  • Serum total ≤ 1.5 × ; if > 1.5 ULN and due to Gilbert syndrome, total bilirubin ≤ 3 × ULN with direct bilirubin ≤ ULN
  • at or below ULN and ALT at or below ULN
  • Alkaline phosphatase (ALP) ≤ 2.5 × ULN
  • Have adequate renal function as evidenced by:
  • Serum creatinine ≤ 2.5 × ULN, OR
  • > 40 mL/min/1.73 m2 based on the Bedside Schwartz method 0.413 × (Height in cm/Serum Creatinine in mg/dL)
  • Have recovered from any toxicities associated with any prior surgery for the treatment of glioma unless stabilized under medical management (functional limitations as a result of prior surgical resections or due to the anatomical location of the tumor will be permitted).
  • Female participants of must have a negative serum pregnancy test before starting medicinal product (IMP).
  • Women of as well as fertile male participants with female partners of reproductive potential, must agree to abstain from sexual intercourse or to use 2 effective methods of from screening until at least 90 days after the last dose of IMP.

Exclusion criteria

Exclusion Criteria:

  • Have had any prior anticancer therapy other than surgery (, sub-total resection, gross-total resection) for treatment of glioma including, but not limited to, systemic chemotherapy, radiotherapy, vaccines, small molecule inhibitors, IDH inhibitors, and agents.
  • Have features assessed as high-risk by the Investigator.
  • Have .
  • Concurrent active except for curatively resected nonmelanoma skin cancer or curatively treated carcinoma in situ. Participants with previously treated malignancies are eligible provided they have been disease-free for 3 years at Screening.
  • Unable to swallow oral medication.
  • Are pregnant or breastfeeding.
  • Are participating in another interventional study at the same time; participation in non-interventional registries or epidemiological studies is allowed.
  • Have a severe or uncontrolled active acute or chronic infection or an unexplained fever > 38.5°C within 7 days of C1D1.
  • Have a known to any of the components of vorasidenib.
  • Have significant active cardiac disease within 6 months before the start of IMP, including Class III or IV congestive heart failure, myocardial infarction, unstable angina, and/or stroke.
  • Have a heart-rate interval using Fridericia's formula (QTcF) ≥ 450 msec or other factors that increase the risk of QT prolongation or arrhythmic events.
  • Are taking therapeutic doses of (defined as > 1.5 mg/day dexamethasone or >10 mg/day prednisone or equivalent) for signs/symptoms of glioma. Participants taking physiologic doses (defined as ≤ 1.5 mg/day dexamethasone or ≤ 10 mg/day prednisone or equivalent) for medical conditions not related to glioma will be permitted.
  • Are taking any medications that are CYP2C19 or substrates with a narrow therapeutic index or strong inhibitors of CYP1A2.
  • Have known active virus (HBV) or virus (HCV) infection, known positive (HIV) antibody results, or AIDS-related illness. Participants with a sustained viral response to HCV treatment or immunity to prior HBV infection will be permitted. Participants with chronic HBV or HIV that is adequately suppressed by institutional practice will be permitted.
  • Have known active inflammatory gastrointestinal disease, chronic diarrhea, previous gastric resection or lap band dysphagia, short-gut syndrome, gastroparesis, or other condition that limits the ingestion or gastrointestinal absorption of drugs administered orally. Gastroesophageal reflux disease under medical treatment is allowed (assuming no drug interaction potential).
  • Have any other acute or chronic medical or psychiatric condition.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Open Label Vorasidenib

    Drug: Vorasidenib

Interventions

  • 40mg taken orally daily for participants weighing ≥ 40 kg OR 20mg taken orally daily for participants weighing ≥ 25 kg to \< 40 kg

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events (AEs) leading to discontinuation, or Adverse Events (AEs) leading to death

    Time frame: From start of treatment through 28 days after last dose for AEs (Safety follow-up), study-related SAEs will be reported through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  2. Severity of AEs

    As assessed by the NCI-CTCAE version 5.0.

    Time frame: From start of treatment through 28 days after last dose for AEs (Safety follow-up), study-related SAEs will be reported through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  3. Height and Weight Percentiles at Study Visits

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  4. Change in Height and Weight Percentiles from Cycle 1 Day 1 (C1D1)

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  5. Tanner staging

    Tanner stages represent puberty progression from stage 1 being the prepubertal form to stage 5 representing the final adult form.

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  6. Average age of menarche

    Historically and/or while on treatment, if applicable

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  7. Change from C1D1 to the worst on-treatment value of leutenizing hormone (LH)

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  8. Change from C1D1 to the worst on-treatment value of follicle-stimulating hormone (FSH)

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  9. Change from C1D1 to the worst on-treatment value of anti-Müllerian hormone (AMH)

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  10. Change from C1D1 to the worst on-treatment value of estradiol

    For females only

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  11. Change from C1D1 to the worst on-treatment value of testosterone

    For males only

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  12. Change from C1D1 to the worst on-treatment value of Insulin-like growth factor 1 (IGF-1)

    Time frame: Cycle 1 Day 1 (C1D1) (each cycle is 28 days long)

  13. Change from C1D1 to the worst on-treatment value of Insulin-Like Growth Factor-Binding Protein 3 (IGFBP-3)

    Time frame: Cycle 1 Day 1 (C1D1) (each cycle is 28 days long)

  14. Change from C1D1 to the worst on-treatment value of thyroid stimulating hormone (TSH)

    Time frame: Cycle 1 Day 1 (C1D1) (each cycle is 28 days long)

  15. Change from C1D1 to the worst on-treatment value of Free T4 (thyroxine)

    Time frame: Cycle 1 Day 1 (C1D1) (each cycle is 28 days long)

  16. Change from C1D1 to the worst on-treatment hand/wrist bone age as determined by X-ray

    Time frame: From start of treatment through long-term follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: Through PFS follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  2. Objective response (OR)

    Time frame: Through PFS follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  3. Best overall response of complete response (CR), partial response (PR), or minor response (mR)

    Time frame: Through PFS follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  4. Time to response (TTR)

    Time frame: Through PFS follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  5. Time to CR, PR, or mR

    Time frame: Through PFS follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  6. Duration of response (DoR)

    Time frame: Through PFS follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  7. Duration of CR, PR, or mR

    Time frame: Through PFS follow-up (approximately 5 years per participant for a total study duration of approximately 7 years)

  8. Plasma concentration of vorasidenib

    Time frame: Through Cycle 3 Day 1 (C3D1) (each cycle is 28 days long)

  9. Plasma concentration of AGI-69460

    Time frame: Through Cycle 3 Day 1 (C3D1) (each cycle is 28 days long)

07

Study locations

8 of 8 sites recruiting
  • UCLA
    Los Angeles, California 90095, United States
    Recruiting
  • UCSF Department of Pediatrics
    San Francisco, California 94158, United States
    Recruiting
  • Lurie Children' sNWU
    Chicago, Illinois 60611, United States
    Recruiting
  • Dana Farber (DFCI)
    Boston, Massachusetts 02115, United States
    Recruiting
  • Children's Minnesota
    Minneapolis, Minnesota 55404, United States
    Recruiting
  • St.Jude Children's
    Memphis, Tennessee 38105, United States
    Recruiting
  • Kids Cancer Centre, Sydney Children's Hospital Randwick
    Sydney, 2031, Australia
    Recruiting
    • David Ziegler · Contact
  • SickKids The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2033, 81 months after the start.

Of 51 phase 2 interventional studies under Astrocytoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 100. This study's planned 81 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 16, 2025
StartActual
Jul 23, 2026
Primary completionEst.
May 2, 2033
CompletionEst.
May 2, 2033
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first site in Canada
Show 3 added (2 United States, 1 Canada)
  • UCSF Department of Pediatrics · San Francisco, United States
  • St.Jude Children's · Memphis, United States
  • SickKids The Hospital for Sick Children · Toronto, Canada
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    3 sites added — first site in Canada
    Show 3 added (2 United States, 1 Canada)
    • UCSF Department of Pediatrics · San Francisco, United States
    • St.Jude Children's · Memphis, United States
    • SickKids The Hospital for Sick Children · Toronto, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07286292
Lead sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Jul 23, 2026
Primary completion
May 2, 2033 (estimated)
Completion
May 2, 2033 (estimated)
Last update
Nov 12, 2026

Study contacts

Institut de Recherches Internationales Servier (I.R.I.S.)
Contact
scientificinformation@servier.com
+33 1 55 72 60 00

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorasidenib

Start the discussion